Literature DB >> 17318198

Targeting of adenovirus vectors carrying a tumor cell-specific peptide: in vitro and in vivo studies.

K Rittner1, V Schreiber, P Erbs, M Lusky.   

Abstract

Previously, we have identified a tumor cell-specific peptide, HEW, by panning of phage display libraries on the human colorectal cancer cell line WiDr. In this report we demonstrate that this peptide can modify the infection properties of adenovirus vectors. Increased infectivity of replication-deficient adenovirus 5 vectors in WiDr cells was observed upon genetic insertion of the HEW peptide in the HI loop of the fiber knob. Moreover, whereas the coxsackie and adenovirus receptor (CAR)-ablating fiber mutation S408E abolished apparent infection in CAR-positive WiDr cells, the insertion of HEW completely restored infectivity toward these cells in vitro. To assess whether the de- and re-targeted infection profile was maintained in vivo, the fiber-modified adenovirus vectors were injected intratumorally or intravenously in WiDr tumor-bearing Swiss nu/nu mice. No significant differences in efficiency of infection could be observed suggesting alternative viral uptake mechanisms in vivo. Next, we have included the fiber shaft mutation S(*) in our studies, which was described to confer a de-targeted phenotype in vivo. Reduced gene transfer due to the S(*) mutation both in vitro and in vivo could be confirmed. Insertion of HEW in the HI knob loop of shaft-mutated fiber, however, did not rescue infectivity in target cells neither in vitro nor in vivo. We demonstrate the efficient ligand-mediated re-targeting of adenoviral vector infection to the human cancer cell line WiDr. The lack of apparent re-targeting in the in vivo situation is described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318198     DOI: 10.1038/sj.cgt.7701036

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

Review 1.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

Review 2.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

3.  Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo.

Authors:  Michael A van Geer; Conny T Bakker; Naoya Koizumi; Hiroyuki Mizuguchi; John G Wesseling; Ronald P J Oude Elferink; Piter J Bosma
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

Review 4.  Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.

Authors:  Kathlynn C Brown
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

5.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

6.  Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

Authors:  Michael Behr; Johanna K Kaufmann; Patrick Ketzer; Sarah Engelhardt; Martin Mück-Häusl; Pamela M Okun; Gabriele Petersen; Frank Neipel; Jessica C Hassel; Anja Ehrhardt; Alexander H Enk; Dirk M Nettelbeck
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

7.  Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells.

Authors:  Shihai Liu; Qinwen Mao; Weifeng Zhang; Xiaojing Zheng; Ye Bian; Dongyang Wang; Huijin Li; Lihong Chai; Junli Zhao; Haibin Xia
Journal:  Biosci Rep       Date:  2009-04       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.